[Developments in cancer care with innovative genomics. 2008 report of the National Cancer Consortium]

Magy Onkol. 2009 Dec;53(4):321-34. doi: 10.1556/MOnkol.53.2009.4.1.
[Article in Hungarian]

Abstract

In the 3rd year of the program 8 new molecular diagnostic services have been introduced to clinic in the management of breast-, lung-, colorectal cancers as well as in GIST and melanoma. Two patents have been filed for innovative modulation of mito/motogenic signaling pathways in cancer cells. In preclinical models of human cancer a functional imaging technique was developed to detect vascular eff ects of erythropoietin. Using a genomic approach, the sequential changes in human melanoma during systemic dissemination were determined revealing several novel potential prognostic factors and some interesting novel targets for therapy.

Publication types

  • English Abstract

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Biomarkers, Tumor / genetics*
  • Bone Neoplasms / secondary
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / genetics
  • Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis
  • Colorectal Neoplasms, Hereditary Nonpolyposis / genetics
  • Female
  • Gastrointestinal Stromal Tumors / diagnosis
  • Gastrointestinal Stromal Tumors / genetics
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Genomics*
  • Humans
  • Hungary
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / genetics
  • Male
  • Melanoma / diagnosis
  • Melanoma / genetics
  • Neoplasms / blood supply
  • Neoplasms / diagnosis*
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • Neovascularization, Pathologic / diagnosis*
  • Pathology, Molecular
  • Pharmacogenetics
  • Prognosis
  • Program Evaluation
  • Risk Factors
  • Signal Transduction / genetics
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / genetics

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor